Vedanta Biosciences “significantly” reduced its headcount to maintain progress and focus resources on a Phase III study of oral drug candidate VE303 for recurrent Clostridioides difficile infection (rCDI).
All entries for: Biologic
January 12, 2026
InflaRx
Discontinued Research, Layoffs
Jena, Germany
51-200 employees
InflaRx is cutting approximately 30% of its employees in a bid to streamline its spending and pour more of its resources into its lead candidate. To accompany the layoffs, InflaRx will also pull money from its investigational antibody Gohibic, according to a press announcement Jan. 8.
Disease Area: Chronic Disease, Immune Diseases, Infectious Diseases
Drug Type: Biologic, Small Molecule
January 8, 2026
Tessera Therapeutics
Layoffs
Somerville, MA
201-500 employees
A month after announcing a partnership with Regeneron to advance its lead gene editor, Tessera Therapeutics has disclosed it will lay off 90 employees. Endpoints News first reported the cuts. Several employees told Endpoints the layoffs will affect about 35% of the workforce. The cuts follow a 17% reduction in 2025 and 13% downsizing in 2024.
Disease Area: Chronic Disease, Multiple, Rare Diseases, Respiratory Diseases
Drug Type: Biologic
January 3, 2026
GSK
Layoffs
London, UK
10,000+ employees
Up to 350 people across GSK’s U.S. and U.K. workforces could lose their jobs as the pharma reorients its investments with its priorities. The layoffs are expected to affect fewer than 70 individuals in the US, and fewer than 50 in the UK, according to Fierce.
Disease Area: Immune Diseases, Multiple, Oncology, Rare Diseases, Respiratory Diseases
Drug Type: Biologic, Small Molecule
December 12, 2025
Pfizer
Layoffs
New York, NY
10,000+ employees
Pfizer will part ways with more than 200 employees across Switzerland as part of a continuing effort to slow its cash burn, according to a report from Bloomberg on Dec. 10. After the layoffs, the pharma expects its Switzerland headcount to shrink to around 70 people, down from 300, the publication noted, citing anonymous sources familiar with the matter.
Disease Area: Multiple, Oncology
Drug Type: Biologic, Small Molecule
November 25, 2025
Novartis
Layoffs
Basel, Baselstadt
10,000+ employees
Novartis will cut 550 full-time jobs at a facility in Switzerland by the end of 2027. The cuts come as the pharma company is ending production of tablets, capsules, and sterile medicine packaging at a plant in Stein, Switzerland.
Disease Area: Cardiology, Hematology, Immune Diseases, Multiple, Oncology
Drug Type: Biologic, Small Molecule
November 20, 2025
Ensoma
Layoffs
Boston, MA
51-200 employees
As it transitions into a clinical-stage company, genetic therapy startup Ensoma is leaving behind half of its employees. CEO Jim Burns confirmed to Endpoints News that only 37 workers will remain with the company.
Disease Area: Rare Diseases
Drug Type: Biologic
November 20, 2025
AbbVie
Layoffs
North Chicago, IL
10,000+ employees
AbbVie is laying off 59 employees across three California sites, effective Jan. 9, according to a Worker Adjustment and Retraining Notification (WARN) Act notice filed Nov. 13. AbbVie will permanently close the Dublin and Livermore sites after Jan. 9.
Disease Area: Oncology
Drug Type: Biologic
November 19, 2025
CERO THERAPEUTICS HOLDINGS, INC.
Negative Outlook
Scottsdale, AZ
51-200 employees
For example, the Medicare Drug Price Negotiation Program, administered by CMS as part of the Inflation Reduction Act of 2022, commonly referred to as the IRA, may apply to our products if they are selected for negotiation, which could materially reduce the amount of revenue we can generate from our products if they are approved.
Disease Area: Oncology
Drug Type: Biologic